On January 14, Shenzhen Stock Exchange and Shanghai Stock Exchange released a week's regulatory dynamics to focus on Aba Chemicals Corporation(300261) (300261) and Shanghai Kaikai Industry Company Limited(600272) (600272) with serious abnormal stock price fluctuations.
Due to the concept of covid-19 oral drug, Aba Chemicals Corporation(300261) has started the soaring mode since December 20, 2021, with an increase of 270% so far; Shanghai Kaikai Industry Company Limited(600272) the share price has doubled since the beginning of the year because it is said on the Internet that it has the national secret formula of Liushen Pill.
Aba Chemicals Corporation(300261) : no products are supplied directly to Pfizer
Before being monitored by the exchange, Aba Chemicals Corporation(300261) has started a round of suspension verification from December 29, 2021 to January 5, 2022. Although the share price has corrected in the first two days after the resumption, it has started a relay rise since January 10. It has harvested two limit boards within five days, with the latest closing of 27.32 yuan / share. The market value has soared by nearly 20 billion yuan in recent months.
Aba Chemicals Corporation(300261) mainly engaged in pesticide intermediates and pharmaceutical intermediates, of which pesticide intermediates accounted for the majority, while the pharmaceutical intermediates business, which accounted for a relatively small proportion, gave birth to this round of rising market.
On November 4, 2021, the company announced on its official website that "the commercialization and mass production of pharmaceutical intermediate carbonic anhydride developed and produced is smooth, and the current monthly production scale has reached 20 tons"; On December 3, China International Capital Corporation Limited(601995) chemical team released the report on paying attention to Pfizer covid-19 Drug Intermediates - isopentenol and inulin, pointing out that carbonic anhydride and its derivatives can be used to synthesize Pfizer covid-19 oral drug palovide from the process flow, and named Aba Chemicals Corporation(300261) with carbonic anhydride synthesis technology in the report. Since early November, Aba Chemicals Corporation(300261) has been easy to "fry the pot", and investors have raised questions about Caron anhydride. Although the company mentioned that the relevant business will not have a significant impact on the performance, it has not replied positively whether to sell products to Pfizer in the early stage. It was not until December 21 that Aba Chemicals Corporation(300261) issued an announcement of stock price changes that it pierced the window paper and frankly said that it did not directly supply long anhydride products to Pfizer at present.
Under the attention of Shenzhen stock exchange for several rounds, Aba Chemicals Corporation(300261) has successively revealed the development stage and future risk points of relevant businesses: there is no cooperative relationship with Pfizer, and the customers of carlon anhydride and its derivatives are mainly Chinese customers and Indian customers. It is impossible to determine whether the company's carlon anhydride and its derivatives are indirectly supplied to Pfizer; In 2021, the sales revenue of related products was 27.073 million yuan, accounting for only 1% - 2% of the total annual revenue. The orders on hand were 63.5408 million yuan, which is not expected to have a significant impact on the current performance.
In terms of performance, the net profit of Aba Chemicals Corporation(300261) in the first three quarters of 2021 was 150 million yuan, with a year-on-year increase of 23.03%. At present, there is no significant change in production and operation. The company admitted that the current stock price increase is significantly higher than the change degree of fundamentals, which does not match the fundamentals.
Shanghai Kaikai Industry Company Limited(600272) : there is no Liushen Pill production business
The sharp rise of Shanghai Kaikai Industry Company Limited(600272) began on December 31, 2021. Nine trading boards were harvested in 10 trading days, and the latest price was 16.5 yuan / share, with a short-term increase of 121%.
According to the data, Shanghai Kaikai Industry Company Limited(600272) is currently mainly engaged in the clothing and pharmaceutical sectors, of which the pharmaceutical sector is mainly carried by the wholly-owned subsidiary Shanghai leiyunshang pharmaceutical West Co., Ltd. (hereinafter referred to as "leiyunshang"). At the end of last year, the stock price of traditional Chinese medicine was stronger on the news of the rise in the price of income and medicinal materials. During this period, Shanghai Kaikai Industry Company Limited(600272) was rumored by the market that the subsidiary leiyunshang had the national confidential formula of "Liushen Pill", which aroused the pursuit of the market. On January 5, the company clarified in the announcement of share price change for the first time, making it clear that the company did not have any national confidential pharmaceutical formula, nor did it have the production business of Liushen Pill. Since then, Shanghai Kaikai Industry Company Limited(600272) has repeatedly emphasized the above information, but the market is still arrogant.
It is worth mentioning that in recent years, Shanghai Kaikai Industry Company Limited(600272) pharmaceutical circulation business has been under continuous pressure due to the impact of medical reform policies such as volume procurement, and began to layout the "big health" business, create a retail development pattern of offline stores and online platforms, and explore new growth points of cloud pharmacy. However, the company said that due to the long cultivation period required for business transformation, the investment income is difficult to show in the short term.
From the performance point of view, Shanghai Kaikai Industry Company Limited(600272) although it has ushered in a pre increase after three consecutive years of decline, the profitability is still low. According to the performance forecast, the company expects to achieve a net profit of RMB 19.82 million-22.56 million in 2021, with a year-on-year increase of 45% to 65%, and the expected earnings per share is RMB 0.08-0.09/share, while the recent profit after deduction is only RMB 3.35 million-5 million.
It is worth mentioning that in a recent change announcement, Shanghai Kaikai Industry Company Limited(600272) reminded investors to beware of the "beating drums and flowers" of hot money in the market, make rational decisions and pay attention to stock investment risks. From the data of the dragon and tiger list, the top five buying and selling seats are mostly hot money, and multiple business departments appear as buyers and sellers at the same time, so the game phenomenon is obvious. Among them, Huatai Securities Co.Ltd(601688) Jiangning Road, Putuo District, Shanghai was listed four times, Guotai Junan Securities Co.Ltd(601211) Kunming Renmin Middle Road, Galaxy Securities Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) street and Galaxy Securities Guangzhou Yuejiang Middle Road business department were listed three times, and appeared in the top five seats.
